Clinical Trial Update: A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection [Phase 1]

View source ↗

Summary

Phase 1 clinical trial updating Janssen compounds JNJ-73763989 and JNJ-64300535, along with nucleos(t)ide analogs, in virologically suppressed, HBeAg-negative c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• JNJ-64300535
• JNJ-73763989
• Nucleos(t)ide analogs

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Hepatitis B, Chronic | Phase 1 | Status: COMPLETED